Rosuvastatin Calcium + Fenofibrate
Rosuvastatin Calcium + Fenofibrate is a combination medication used for the management of dyslipidemia. It combines the benefits of a statin and a fibrate to effectively lower cholesterol and triglyceride levels, reducing cardiovascular risk.
Mechanism of Action:
- Rosuvastatin Calcium:
- A statin that inhibits HMG-CoA reductase, reducing the production of cholesterol in the liver.
- Lowers LDL-C (low-density lipoprotein cholesterol), total cholesterol, and triglycerides, while increasing HDL-C (high-density lipoprotein cholesterol).
- Fenofibrate:
- A fibrate that activates peroxisome proliferator-activated receptor-alpha (PPAR-α).
- Enhances the breakdown and clearance of triglyceride-rich lipoproteins, effectively lowering triglycerides and increasing HDL-C.
- Recommended Usage
Indications:
- Mixed dyslipidemia (elevated LDL-C, triglycerides, and reduced HDL-C).
- Severe hypertriglyceridemia.
- Dyslipidemia in patients with metabolic syndrome or high cardiovascular risk.
Dosage and Administration:
- Adults:
- Rosuvastatin: 5–20 mg once daily.
- Fenofibrate: Typically 145 mg once daily.
- Dosage adjustments should be individualized based on lipid profile and tolerance.
- Take the medication with or without food.
Precautions:
- Hepatotoxicity: Monitor liver function tests periodically. Discontinue if significant elevations in liver enzymes occur.
- Myopathy/Rhabdomyolysis: Risk increases with concomitant use of other lipid-lowering agents or in patients with renal impairment. Monitor for muscle pain or weakness.
- Renal Impairment: Fenofibrate requires dose adjustments in patients with renal dysfunction.
- Pregnancy and Lactation: Contraindicated during pregnancy (category X) and not recommended while breastfeeding.
- Drug Interactions: Avoid concomitant use with other fibrates or high-dose statins.
Key Benefits:
- Comprehensive Lipid Control: Reduces LDL-C and triglycerides while increasing HDL-C.
- Dual Mechanism: Synergistic action of statins and fibrates addresses both cholesterol and triglycerides.
- Cardiovascular Risk Reduction: Improves lipid profiles in high-risk patients, reducing the likelihood of cardiovascular events.
- Convenient Dosage: Combination therapy simplifies treatment regimens.
